# A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography

> **NCT07740421** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Trust Bio-sonics, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Cardiac Diseases

## Interventions

- **DRUG:** NH002 (Perflutren Lipid Microspheres) Injectable Suspension

## Key facts

- **NCT ID:** NCT07740421
- **Lead sponsor:** Trust Bio-sonics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07740421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07740421, "A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07740421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*